

ORIGINAL ARTICLE

Effect of thoracic epidural analgesia on clinical outcomes following transapical transcatheter aortic valve implantation

Ignacio J Amat-Santos,¹ Eric Dumont,¹ Jacques Villeneuve,¹ Daniel Doyle,¹ Michel Rheault,¹ Dominique Lavigne,¹ Jérôme Lemieux,¹ André St-Pierre,¹ Michael Mok,¹ Marina Urena,¹ Luis Nombela-Franco,¹ Steve Blackburn,¹ Mathieu Simon,¹ Christine Bourgault,¹ José Luis Carrasco,¹ Philippe Pibarot,¹ Melanie Côté,¹ Robert DeLarochelière,¹ David J Cohen,² Josep Rodés-Cabau¹

See Editorial p1441

¹Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
²Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri, USA

Correspondence to

Dr Josep Rodés-Cabau, Quebec Heart Lung Institute, Laval University, 2725 chemin Ste-Foy, G1V 4G5 Quebec city, QC G1V 4G5, Canada; josep.rodés@cricupq.ulaval.ca

Accepted 11 June 2012

Published Online First
 11 July 2012

ABSTRACT

Objective To determine the impact of perioperative thoracic epidural analgesia (TEA) on acute and late outcomes following transapical transcatheter aortic valve implantation (TA-TAVI).

Patients and intervention A total of 135 consecutive patients who underwent TA-TAVI were included. All patients received catheter-based pain control, either via TEA (TEA group, n=74) or intercostal local analgesia with a catheter placed at the surgical incision site (non-TEA group, n=61), depending on the preference of the anaesthesiologist responsible for the case.

Main outcome measures Pain level during early postoperative period (verbal rating scale from 1 to 10), 30-day/in-hospital complications and mortality, and 1-year mortality.

Results There were no differences in baseline or procedural characteristics between groups except for a lower left ventricular ejection fraction in the TEA group. The maximal pain score related to thoracotomy in the postoperative period was higher in the non-TEA group as compared with the TEA group (4 (IQR: 3–5)) vs 2 (IQR: 1–3), $p<0.001$). Non-TEA was associated with a higher rate of pulmonary complications ($p<0.05$ for nosocomial pneumonia, reintubation and tracheostomy). The 30-day/in-hospital mortality rate was higher in the non-TEA group (22.9% vs 2.7% in the TEA group, $p<0.001$). At 1-year follow-up, overall mortality remained higher in the non-TEA group (31.1%) compared with the TEA group (10.8%), $p=0.005$. Similar periprocedural and late results were obtained in a propensity score-matched analysis that included 100 matched patients. In the multivariable analysis, STS score ($p=0.027$) and absence of TEA ($p=0.039$) were independent predictors of increased cumulative late mortality.

Conclusions TEA provided superior analgesia following TA-TAVI, and was associated with a dramatic reduction in periprocedural respiratory complications, and both, short- and long-term mortality. These results highlight the importance of obtaining optimal analgesia following TA-TAVI to improve the results associated with this procedure.

INTRODUCTION

The transapical approach (TA) has been widely used as an alternative to the transfemoral approach in those patients with unsuitable iliofemoral vascular access undergoing transcatheter aortic valve implantation (TAVI).^{1,2} However, some data have suggested poorer acute and midterm outcomes associated with this approach as compared with the transfemoral approach.^{3–7} This has been partially explained by the higher risk profile of those patients selected for the TA approach, but very few data exist on the potential deleterious consequences of thoracotomy in the very old and high-risk patients who are most commonly selected for TAVI.

Provision of adequate postoperative analgesia is a key determinant of clinical outcomes following thoracic surgery.⁸ Thoracotomy may be associated with severe postoperative pain which may lead to a further worsening of pulmonary function and an increased risk of severe pulmonary complications and death. Thoracic epidural analgesia (TEA) has been shown to provide better pain control and improve clinical outcomes following thoracotomy for cardiovascular or thoracic interventions.^{8–11} However, very few data exist on postoperative chest pain and its potential clinical consequences following TA-TAVI, or on the use of TEA in TA-TAVI procedures.¹² The objective of our study was, therefore, to evaluate the effects of TEA on reducing postoperative pain and improving clinical outcomes following TA-TAVI.

METHODS

A total of 135 consecutive patients with severe symptomatic aortic stenosis who underwent TA-TAVI with a balloon-expandable valve (Edwards SAPIEN or SAPIEN XT, Edwards Lifesciences, Irvine, California, USA) at our institution were included. Details about the TA-TAVI procedure have been extensively explained in previous studies.¹³

Anaesthesia and postoperative analgesia protocol

All patients were premedicated with 0.05 mg/kg of midazolam on the day of the procedure. Induction was done with bolus doses of either ketamine or etomidate and rocuronium, and all patients were intubated orally. Anaesthesia was maintained with

sevoflurane and continuous infusion or intermittent boluses of midazolam, remifentanyl, fentanyl or sufentanyl, which were used according to clinical status and procedural requirements.

The decision to place an epidural catheter for perioperative analgesia was determined by the primary anaesthesiologist for the procedure, and depended primarily on his experience and comfort level with the technique. In accordance with the recommendations of the American Society of Regional Anaesthesia and Pain Medicine,¹⁴ epidural analgesia was not performed in patients with an underlying coagulopathy. The catheter was placed in the T7–T8 intervertebral space, with a 17-gauge epidural needle, and the correct position was verified by the loss of resistance using air or saline. Epidural catheter insertion was performed before the induction of the anaesthesia to allow at least an hour's delay between the puncture and the administration of heparin in order to decrease the risk of an epidural haematoma in case of unrecognised bleeding from the puncture. An initial bolus of bupivacaine (8 cc, 0.25%) and fentanyl (2 cc, 50 µg/cc) was administered immediately before the induction of general anaesthesia, and was followed by a continuous infusion of the two drugs (bupivacaine 0.1%, fentanyl 5 µg/cc, 0.1 cc/kg/hr) for at least 3 days. The infusion was adjusted depending on pain level and respiratory rate. In those patients without TEA, an intercostal catheter of 17 gauge was inserted inside the surgical wound at the end of the intervention, and ropivacaine (0.2%, bolus of 15 cc, followed by an infusion at 15 cc/h) was administered for at least 3 days. The adequacy of pain control was recorded through a verbal rating scale from 0 to 10 and documented in the nursing report sheet every hour until complete pain relief in both groups. Supplemental analgesia with rectal or oral paracetamol, and subcutaneous or intravenous opioids, was administered in both groups as required.

Postoperative and follow-up outcomes

All periprocedural complications were prospectively recorded and defined according to the VARC criteria.¹⁵ Patients were on continuous ECG monitoring until hospital discharge, and new-onset atrial fibrillation (NOAF) was defined as any episode of AF lasting longer than 30 s. Follow-up was performed by means of clinical visits or telephone contact at 30 days, 6 months and 12 months, and annually thereafter, and was available in 100% of the study population. Late cardiovascular events were defined according to the VARC criteria.¹⁵

Statistical analysis

Group comparisons were performed using Student's t-test or the Wilcoxon test for continuous variables, and χ^2 test or Fisher's exact test for categorical variables. A propensity score matching analysis was performed to adjust for the intergroup (TEA vs non-TEA) differences in baseline characteristics caused by the selection bias inherent to the non-randomised nature of the study. By using a logistic regression analysis, the probability of being assigned to TEA versus non-TEA was calculated from baseline and procedural characteristics. Variables exhibiting a p value <0.20 in the univariable analysis were included in the logistic regression analysis. Selected variables were age, diabetes, dyslipidemia, chronic obstructive pulmonary disease, STS-PROM score and left ventricular ejection fraction. By using these covariables, a propensity score was calculated for each patient, and patients of the two groups (TEA vs non-TEA) were matched using a one-to-one matching process. The maximum difference of propensity score for a match was established at 10%. Comparable patient groups, including a total of 100 patients

(TEA group: 50 pts, non-TEA group: 50 pts), were identified for analysis. A Cox multivariable analysis including all variables with p value <0.05 in the univariable analysis was used to determine the predictive factors of cumulative late mortality. Late outcomes were also assessed by Kaplan–Meier estimates and compared using the log-rank test. The results were considered significant with p values <0.05. Statistical analyses were performed with the statistical package SAS, V.9.2 (SAS Institute Inc).

RESULTS

The main clinical, echocardiographic and procedural characteristics of the study population and the TEA and non-TEA groups are shown in table 1. The mean gradient decreased to 12.1 ± 7.5 mm Hg, and valve area increased to 1.48 ± 0.34 cm² following the intervention (p<0.001 vs baseline for both), with no differences between TEA and non-TEA groups (p>0.20 for both, mean gradient and valve area). Some degree of residual aortic regurgitation was observed in 67% of the patients, and was trivial or mild in 59% and mild to moderate in 8% of the patients, respectively, with no differences (p=0.63) between groups.

Postoperative analgesia and mechanical ventilation times

Maximal pain scores at different time periods following TA-TAVI grouped according to the type of postoperative analgesia (TEA vs non-TEA) are shown in figure 1. The median maximum pain scores during the postoperative period were 2 (1–3) and 4 (3–5) in the TEA and non-TEA groups, respectively (p<0.0001). The median pain scores during the first 24 h (TEA: 1 (1–2), non-TEA: 4 (3–5)), at 24–48 h (TEA: 1 (1–2), non-TEA: 2 (2–3)), at 48–72 h (TEA: 1 (0–1), non-TEA: 1 (1–2)), and after 72 h up to hospital discharge (TEA: 0 (0–1), non-TEA: 1 (1–2)) following the procedure were higher in the non-TEA group as compared with the TEA group (p<0.0001 for all time periods). The catheter for regional analgesia was removed at a median time of 4 (3–4) days, with no differences between groups (TEA: 4 (3–4) days, non-TEA: 4 (3–4) days, p=1.00). After the first 72 h, 98% of the patients in the TEA group had no or minimal (score=0–1) surgical wound pain as compared with 64% of patients in the non-TEA group (p<0.0001). Up to 57% of the patients in the TEA group presented no surgical wound pain (score=0) compared with only 16% of the patients in the non-TEA group (p<0.0001). One patient suffered an epidural catheter migration the second day after surgery with no clinical consequences. There were no haemodynamic, bleeding or neurological complications related to epidural or intercostal catheters. The rate of TEA use was similar in the first and second halves of the study period (51% vs 58%, p=0.54).

The median orotracheal intubation time was 6 h (6–8 h), and it was significantly longer in the non-TEA group than in the TEA group (7 (6–24) h, vs 6 (6–7) h, p=0.001). In the TEA group, 93.2% of the patients were extubated within 12 h following the intervention, as compared with 73.8% of the patients in the non-TEA group (p=0.003). Ororacheal intubation of >48 h was more frequent in the non-TEA group (14.8%) as compared with the TEA group (2.7%), p=0.023.

Periprocedural events

The main periprocedural (30-day/in-hospital) events are shown in table 2. The 30-day/in-hospital mortality rate was 11.9%, and the main characteristics and causes of death of all patients who died within 30 days, or before hospital discharge following TAVI, are summarised in table 3. Of the 16 patients who died at 30 days, or before hospital discharge, a total of seven patients (44%) died due to respiratory complications, and all of them

Table 1 Baseline and procedural characteristics of the study population (n=135), according to the use of thoracic epidural analgesia

	Study population n = 135	Thoracic epidural analgesia		p Value
		No n = 61	Yes n = 74	
Baseline variables				
Age, years	79±8	80±9	78±8	0.072
Males	54 (40.0)	26 (42.6)	29 (39.2)	0.600
Diabetes	51 (37.8)	19 (31.2)	32 (43.2)	0.159
Dyslipidemia	113 (83.7)	48 (78.7)	65 (87.8)	0.168
Hypertension	126 (93.3)	58 (95.1)	68 (91.9)	0.512
Coronary artery disease	89 (65.9)	38 (62.3)	51 (68.9)	0.468
Previous myocardial infarction	57 (42.2)	26 (42.6)	31 (41.9)	1.00
Previous atrial fibrillation	35 (25.9)	15 (24.6)	20 (27.0)	0.844
Prior CABG	55 (40.7)	23 (37.7)	32 (43.2)	0.598
Prior stroke	6 (4.4)	2 (3.3)	4 (5.4)	0.689
Peripheral vascular disease	60 (44.4)	27 (44.3)	33 (44.6)	1.00
COPD	44 (32.6)	25 (40.9)	19 (25.7)	0.067
FEV ₁ (%)*	60±17	58±17	65±17	0.336
eGFR <60 ml/min	88 (65.2)	38 (62.3)	50 (67.6)	0.588
STS-PROM score (%)	8.4±4.4	9.2±5.2	7.7±3.4	0.121
Frailty	19 (14.1)	9 (14.8)	10 (13.5)	1.00
Severely calcified or porcelain aorta	42 (31.1)	17 (27.9)	25 (33.8)	0.576
Echocardiographic variables				
Mean aortic gradient (mm Hg)	41±16	42±16	40±17	0.463
Aortic valve area (cm ²)	0.63±0.19	0.62±0.15	0.64±0.22	0.650
LVEF (%)	53±14	56±13	51±14	0.047
LVEF<40	23 (17.0)	7 (11.5)	16 (21.6)	0.167
SPAP (mm Hg)	44±14	45±13	43±14	0.342
Moderate/severe mitral regurgitation	41 (30.4)	21 (34.4)	20 (27.0)	0.452
Procedural variables				
Type of valve				
Edward XT	8 (5.9)	3 (4.9)	5 (6.7)	0.729
Edward SAPIEN	128 (94.1)	58 (95.1)	70 (93.2)	
Valve size				
23 mm	76 (56.3)	34 (55.7)	42 (56.8)	0.820
26 mm	54 (40.0)	24 (39.3)	30 (40.5)	
29 mm	5 (3.7)	3 (4.9)	2 (2.7)	
Procedural success	129 (95)	57 (93.4)	73 (97.7)	0.175
Valve embolisation	0	0	1 (1.4)	1.00
Valve in valve	5 (3.7)	4 (6.6)	1 (1.4)	0.175
Conversion to open heart surgery	1 (0.7)	1 (1.6)	0	0.452
Invasive haemodynamic parameters				
Cardiac output preimplant (l/min)	3.41±1.31	3.44±1.48	3.39±1.60	0.860
Cardiac output postimplant (l/min)	4.19±1.60	4.13±1.78	4.25±1.45	0.702
SPAP preimplant (mm Hg)	35±11	34±11	35±10	0.483
SPAP postimplant (mm Hg)	40±12	41±12	39±12	0.228
SVR preimplant (dyne·s/cm ⁵)	2035±808	2039±763	2031±849	0.955
SVR postimplant (dyne·s/cm ⁵)	1694±769	1728±709	1665±820	0.677
PVR preimplant (dyne·s/cm ⁵)	223±132	237±143	211±121	0.276
PVR postimplant (dyne·s/cm ⁵)	234±142	261±171	211±109	0.084

Values are mean±SD, n (%).

*Only available in patients with history of COPD.

CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; FEV₁, forced expiratory volume in 1 s; LVEF, left ventricular ejection fraction; PVR, pulmonary vascular resistance; SPAP, systolic pulmonary artery pressure; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; SVR, Systemic vascular resistance.


were in the non-TEA group. The 30-day/in-hospital mortality rate was significantly higher in the non-TEA group (22.9%) compared with the TEA group (2.7%), $p < 0.001$.

Late outcomes

Median follow-up of the study population was 12 (9–24) months, with no differences between the TEA (12 (7–22) months) and non-TEA (13 (12–33) months) groups, $p = 0.12$. Survival curves up to 1-year follow-up are shown in figure 2.

Although there were no differences in late cardiovascular events or mortality beyond the perioperative period, 1-year mortality remained significantly higher in the non-TEA group as compared with the TEA group (31.1% vs 10.8%, $p = 0.005$). Univariable and multivariable predictors of cumulative late mortality are shown in table 4. The independent predictors of cumulative late mortality in the multivariable analysis were the STS score (HR: 1.10 for each increase of 1%, 95% CI 1.01 to 1.20, $p = 0.027$) and the non-use of TEA (HR: 2.39, 95% CI 1.04 to 5.49, $p = 0.039$).

Figure 1 Postoperative pain scores at different time periods, grouped according to the use of thoracic epidural analgesia TEA: thoracic epidural analgesia.



Propensity score-matched cohort

There were no differences in baseline characteristics between TEA and non-TEA groups among the 100 patients (TEA=50, non-TEA=50) included in the propensity score-matched cohort (table 5). Perioperative and late events of the propensity-matched cohort are shown in table 6. Similar to the global study population analyses, TEA was associated with a lower rate of respiratory complications ($p < 0.001$), NOAF ($p < 0.001$), and a smaller increase in CK-MB ($p = 0.038$). The 30-day/in-hospital

and 1-year mortality rates were lower in the TEA group ($p < 0.05$). The Kaplan–Meier survival curves for the propensity score-matched TEA and non-TEA groups are shown in figure 3.

DISCUSSION

Several studies have shown that TEA is very effective in ensuring appropriate pain control following thoracic surgery, and some authors consider this anaesthetic technique to be the

Table 2 Acute and late outcomes, according to the use of thoracic epidural analgesia

Variables	Study population n = 135	Thoracic epidural analgesia		p Value
		No n = 61	Yes n = 74	
30-day/in-hospital outcomes				
Orotracheal reintubation	16 (11.9)	14 (22.9)	2 (2.7)	<0.001
Tracheostomy	6 (4.4)	6 (9.8)	0	0.007
Pneumonia	11 (8.1)	9 (14.8)	2 (2.7)	0.022
Respiratory complications*	22 (16.3)	20 (32.8)	2 (2.7)	<0.001
Sepsis	12 (8.9)	10 (16.4)	2 (2.7)	0.006
Haemodialysis	3 (2.2)	1 (1.6)	2 (2.7)	0.677
Stroke	7 (5.2)	3 (4.9)	4 (5.4)	1.00
Myocardial infarction	2 (1.5)	2 (3.3)	0	0.202
Peak CK-MB (ug/l)	22.0 (16.1–32.0)	26.5 (19.1–37.6)	19.8 (15.0–30.0)	0.002
Peak cardiac troponin T (ug/l)	0.74 (0.51–1.04)	0.80 (0.52–1.34)	0.73 (0.47–0.93)	0.013
New-onset atrial fibrillation	38 (28.1)	28 (45.9)	10 (13.5)	<0.001
Major bleeding	23 (17.0)	13 (21.3)	10 (13.5)	0.253
Hospital length (days, IQR)	8 (7–13)	10 (7–16)	8 (6–10)	0.015
30-day death	14 (10.3)	12 (19.7)	2 (2.7)	0.002
In-hospital death	16 (11.9)	14 (22.9)	2 (2.7)	<0.001
30 day/in-hospital death	16 (11.9)	14 (22.9)	2 (2.7)	<0.001
Late (>30-day/in-hospital to 1-year) outcomes				
Stroke	1 (0.7)	0	1 (1.4)	1.00
Myocardial infarction	1 (0.7)	1 (1.6)	0	0.444
Death	11 (8.1)	5 (8.2)	6 (8.1)	0.750
Late (1-year) cumulative outcomes				
Stroke	8 (5.9)	3 (4.9)	5 (6.8)	0.729
Myocardial infarction	3 (2.2)	3 (4.9)	0	0.089
Death	27 (20.0)	19 (31.1)	8 (10.8)	0.005

Values are mean ± SD, n (%) or median (IQR).

*Pneumonia or respiratory failure leading to reintubation and/or tracheostomy.

CK-MB: Creatine kinase-MB.


Table 3 Characteristics of patients who died at 30 days or in-hospital (n=16)

Age	STS-PROM score (%)	Epidural analgesia	Time to death (days from procedure)	Cause of death
71	8.1	No	4	Mesenteric ischaemia (septic shock)
72	10.1	Yes	10	Ischaemic colitis
76	7.5	No	2	Cardiogenic shock
77	6.9	No	27	ARDS
79	11.5	Yes	2	Cardiogenic shock
81	3.3	No	16	ARDS
85	5.3	No	28	Sudden death
85	13.4	No	4	Cardiogenic shock
85	12.1	No	17	Pneumonia (septic shock)
85	26.1	No	44	Respiratory failure
86	6.1	No	13	Cardiac failure
86	21.4	No	15	Pneumonia (septic shock)
88	5.4	No	15	Pneumonia (septic shock)
88	6.3	No	10	Respiratory failure
96	15.3	No	3	Cardiogenic shock
98	21.9	No	35	Cardiogenic shock

STS-PROM: Society of Thoracic Surgeons predicted risk of mortality; ARDS: acute respiratory distress syndrome.

gold standard for postoperative analgesia following thoracic interventions.^{8–12 16} Since lateral thoracotomy may be more painful than mid-sternotomy due to rib spreading and intercostal nerve injury,¹⁷ optimization of postoperative analgesia might be even more important in such cases. Nonetheless, the use of TEA in patients undergoing TA-TAVI has been limited to a single case report,¹² and no studies, to date, have evaluated the efficacy and safety of this technique of anaesthesia in this setting. The present study showed that TEA was highly effective in providing postoperative analgesia following TA-TAVI. About 50% of the patients treated with TEA experienced either no pain or only minimal pain within the first 48 h following the procedure, and >90% at later time-points, and these pain score

Figure 2 Kaplan–Meier survival curves at 12-month follow-up in patients with and without thoracic epidural analgesia during the TA-TAVI procedure TEA: thoracic epidural analgesia.



levels were far lower than those observed in patients treated with intercostal local analgesia.

Some concerns have been raised about potential complications associated with TEA, such as epidural haematoma in the setting of cardiac surgery, especially because of the use of antithrombotic therapies.¹⁸ However, several studies have shown that TEA is safe in this setting,^{8–11 18} and recent studies have also suggested that anticoagulant therapy is safe in the presence of, or upon removal of, an epidural catheter.^{19 20} Consistent with these previous reports, we observed no local complications associated with TEA despite the use of antithrombotic therapy both before and after insertion of the epidural catheter. Concerns have also been raised regarding the use of epidural anaesthesia in patients with aortic stenosis because of the risk of severe hypotension. However, there have been several reports on the safety of using epidural anaesthesia for non-cardiac and cardiac surgery in the presence of aortic stenosis,^{21–23} and the present study also showed that this approach was not associated with any significant haemodynamic complication in patients undergoing TA-TAVI.

The use of TEA has been associated with a lower rate of cardiovascular complications following cardiac or thoracic surgery.^{9–11} Several studies have shown a significant reduction in NOAF after cardiac surgery, most likely due to the sympatholytic effects of TEA. We recently reported that NOAF is a frequent complication following TAVI, especially with the TA approach.²⁴ The present study showed that TEA was associated with a significant reduction in AF episodes, with more than a fivefold decrease in the incidence of NOAF after TA-TAVI. In addition, some studies have suggested a reduction in myocardial ischaemia and infarction with epidural analgesia following cardiac and non-cardiac surgery.^{8–11} We have previously shown that TA-TAVI is systematically associated with some degree of myocardial injury as evaluated by cardiac biomarker rise.²⁵ While puncture of the left ventricular apex is probably the main cause of post-procedural cardiac biomarker rise, the reduction in myocardial injury with TEA observed in the present study suggests that other mechanisms are also involved. Most patients

Table 4 Univariable and multivariable predictors of cumulative late mortality

	Univariable model		Multivariable model	
	HR (95% CI)	p Value	HR (95% CI)	p Value
eGFR <60 ml/min	2.27 (1.03 to 4.98)	0.041	2.22 (0.86 to 5.76)	0.099
STS-PROM score (%)	1.09 (1.04 to 1.16)*	0.001	1.10 (1.01 to 1.20)*	0.027
Frailty	2.44 (1.05 to 5.70)	0.039	1.96 (0.82 to 4.67)	0.129
No thoracic epidural analgesia	2.59 (1.19 to 5.65)	0.016	2.39 (1.04 to 5.49)	0.039

*For each increase of 1%.

eGFR: estimated glomerularfiltration rate; STS-PROM: Society of Thoracic Surgeons predicted risk of mortality.

with severe aortic stenosis have some degree of myocardial hypertrophy, and the hyperadrenergic response associated with non-optimal analgesia following TA-TAVI might be associated with higher perioperative myocardial oxygen consumption leading to myocardial ischaemia and greater cardiac biomarker rise. Also, the higher incidence of NOAF episodes in the absence of TEA may have contributed to the greater degree of myocardial injury observed in this group.

Thoracic surgery has been associated with a postoperative worsening in pulmonary function due to diaphragmatic dysfunction, decreased chest wall compliance and pain-limited inspiration, and this might translate into a higher incidence of postoperative atelectasia pneumonia and hypoxaemia.^{8,26} Indeed, the deleterious effects of thoracotomy on pulmonary function might be even more pronounced in elderly patients, who frequently exhibit a reduced pulmonary capacity prior to the intervention.²⁷ The use of TEA in thoracic and cardiac surgery has been associated with a significant improvement in postoperative pulmonary function, shorter time to extubation, and a lower rate of pulmonary complications, such as pneumonia or

respiratory insufficiency.^{8,23,28} The present study showed that TEA was associated with a more rapid extubation time and a dramatic reduction in pulmonary complications, such as nosocomial pneumonia, or the need for orotracheal reintubation or tracheostomy due to respiratory failure following TA-TAVI. Of note, pulmonary complications were the cause of death in about half of the patients who died during the postoperative period, and all fatal pulmonary complications occurred in patients who did not receive TEA for perioperative analgesia. This, in turn, translated into a risk of perioperative mortality that was approximately nine times greater among those patients not receiving TEA (approximately six times greater after propensity matching), strongly suggesting an important role for TEA in reducing pulmonary complications and improving clinical outcomes (including survival) following TA-TAVI. The use of TEA has been associated with an improvement in survival following cardiac surgery and intermediate to high-risk non-cardiac surgery.^{9–11,29} This postoperative mortality reduction with TEA has been partially attributed to a reduction in surgical stress response, cardiac complications, pulmonary complications, infectious complications and postoperative pain.

The dramatic effect of TEA on mortality in our study might be related to the characteristics of the study population, with a combination of very advanced age, severe aortic stenosis and a high prevalence of major cardiac and non-cardiac comorbidities, such as cardiac failure, pulmonary hypertension, chronic obstructive pulmonary disease or frailty. Thoracotomy probably has a more pronounced deleterious impact in this very high-risk group of patients. Interestingly, Kempfert *et al*³⁰ have recently reported that a reduced pulmonary capacity was the most important predictive factor of worse outcomes in a large series of patients undergoing TA-TAVI. It is therefore not surprising that any measure leading to a reduction of the negative effects of thoracotomy, such as the use of TEA, translates into major improvement in clinical outcomes. Recent large multicenter TAVI studies have reported 30-day and 1-year mortality rates associated with TA-TAVI of ~12% and ~30%, respectively,^{3–7} rates that are somewhat higher than those reported for patients treated via the transfemoral approach in the same studies. Also, the PARTNER investigators have reported that among patients at high risk of surgical complications, TA-TAVI did not result in any measurable quality-of-life benefits at 1- and 6-month follow-up, as compared with surgical aortic valve replacement, findings that differed from the substantial early quality-of-life benefits of TAVI among patients suitable for the transfemoral approach.³¹ While these findings might be explained in part by the higher risk profile of the patients treated by TA approach, the present study provides important insight into the prognostic importance of postoperative pain management in such patients. The absence of fatal pulmonary complications and the very low perioperative mortality rate (<3%) in the TEA group as compared with the non-TEA group (>20%) strongly suggest that optimisation of postoperative care/analgesia might be a key factor to improve

Table 5 Baseline characteristics of the propensity score-matched cohort (n=100), according to the use of thoracic epidural analgesia

	Thoracic epidural analgesia		p Value
	No n=50	Yes n=50	
Age, years	80±9	78±8	0.281
Males	22 (44.0)	18 (36.0)	0.541
Diabetes	17 (34.0)	19 (38.0)	0.835
Dyslipidemia	42 (84.0)	43 (86.0)	1.00
Hypertension	47 (94.0)	47 (94.0)	1.00
Coronary artery disease	33 (66.0)	35 (70.0)	0.831
Previous myocardial infarction	23 (46.0)	21 (42.0)	0.841
Previous atrial fibrillation	15 (30.0)	13 (26.0)	0.824
Prior CABG	21 (42.0)	18 (36.0)	0.682
Prior stroke	2 (4.0)	4 (8.0)	0.678
Peripheral vascular disease	19 (38.0)	27 (54.0)	0.160
COPD	16 (32.0)	16 (32.0)	1.00
eGFR <60 ml/min	31 (62.0)	35 (70.0)	0.527
STS-PROM score (%)	9.1±5.5	8.4±3.8	0.567
Frailty	8 (16.0)	9 (18.0)	1.00
Severely calcified or porcelain aorta	14 (28.0)	16 (32.0)	0.828
Mean aortic gradient (mm Hg)	42.3±16.6	40.4±17.0	0.566
Aortic valve area (cm ²)	0.62±0.16	0.67±0.23	0.266
LVEF (%)	55±13	54±12	0.809
LVEF<40	6 (12.0)	9 (18.0)	0.579
SPAP (mm Hg)	46±13	43±13	0.403
Moderate/severe mitral regurgitation	19 (38.0)	14 (28.0)	0.395

Values are mean±SD, n (%).

CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerularfiltration rate; LVEF, left ventricular ejection fraction; PAP, systolic pulmonary artery pressure; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality.

Table 6 Acute and late outcomes of the propensity score-matched cohort (n=100), according to the use of thoracic epidural analgesia

Variables	Thoracic epidural analgesia		p Value
	No n=50	Yes n=50	
30-day/in-hospital outcomes			
Orotracheal reintubation	10 (20.0)	1 (2.0)	0.004
Tracheostomy	5 (10.0)	0	0.056
Pneumonia	8 (16.0)	2 (4.0)	0.046
Respiratory complications*	16 (32.0)	2 (4.0)	<0.001
Sepsis	9 (18.0)	2 (4.0)	0.025
Stroke	3 (6.0)	3 (6.0)	1.00
Myocardial infarction	1 (2.0)	0	0.315
Peak CK-MB (ug/l)	24.5 (18.1–32.9)	19.8 (15.3–30.0)	0.038
Peak cardiac troponin T (ug/l)	0.74 (0.52–1.32)	0.76 (0.50–0.95)	0.343
New-onset atrial fibrillation	26 (52.0)	8 (16.0)	<0.001
Major bleeding	10 (20.0)	8 (16.0)	0.569
Hospital length (days, IQR)	10 (7–16)	8 (7–10)	0.058
30-day death	10 (20.0)	2 (4.0)	0.014
In-hospital death	12 (24.0)	2 (4.0)	0.004
30 day/in-hospital death	12 (24.0)	2 (4.0)	0.004
Late (>30-day/in-hospital to 1-year) outcomes			
Stroke	0	1 (2.0)	1.00
Myocardial infarction	0	0	–
Death	3 (6.0)	4 (8.0)	1.00
Late (1 year) cumulative outcomes			
Stroke	3 (6.0)	4 (6.0)	1.00
Myocardial infarction	1 (2.0)	0	0.315
Death	15 (30.0)	6 (12.0)	0.026

Values are n (%) or median (IQR).

*Pneumonia or respiratory failure leading to reintubation and/or tracheostomy.
CK-MB, Creatine kinase-MB.


clinical outcomes in the very high-risk group of patients undergoing TA-TAVI. This is further supported by the fact that, in addition to the STS score, the non-use of TEA remained the most important predictor of mortality at midterm follow-up. The confirmation of these results in larger studies would represent a paradigm shift in the perioperative management of such

patients that could yield substantial reductions in morbidity and improved short- and long-term survival following TA-TAVI.

Study limitations

The main limitation of this study is its non-randomised nature. However, we do not believe that confounding was the main

Figure 3 Kaplan–Meier survival curves at 12-month follow-up in patients with and without thoracic epidural analgesia during the TA-TAVI procedure for the propensity score-matched cohort (n=100) TEA: thoracic epidural analgesia.



explanation for our findings since the selection of patients for TEA was based mainly on the comfort level of the anaesthesiologist with this technique, which led to similar patient characteristics in the two groups. The fact that our results were similar in both risk-adjusted and propensity-matched analyses lends further support to the validity of our findings. Nonetheless, future randomised studies will be necessary to confirm these findings. Although no complications were associated with the use of the epidural catheter, larger studies are needed to further demonstrate the safety of TEA in TA-TAVI procedures.

In conclusion, perioperative analgesia management with TEA was associated with a dramatic reduction in pulmonary and cardiovascular complications and death following TA-TAVI for the treatment of severe aortic stenosis in patients considered to be at very high or prohibitive surgical risk. These findings highlight the importance of the potential negative effects of thoracotomy in this challenging group of elderly patients with multiple comorbid conditions. The results of this study strongly suggest that the optimisation of the perioperative management, and particularly postoperative analgesia following TA-TAVI, would represent a major step forward in improving the results associated with these procedures.

Contributors All authors have read and approved submission of the manuscript. All authors have contributed to this work as follows: (1) substantial contributions to the conception and design, acquisition of data or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published.

Funding Dr IJA-S received support from the Institute of Heart Sciences (ICICOR, Clinical Hospital of Valladolid, Spain).

Competing interests Dr ED is consultant for Edwards Lifesciences; Dr DJC has received research grant support from Edwards Lifesciences and Medtronic Inc. Dr JR-C is consultant for Edwards Lifesciences and St Jude Medical.

Ethics approval The study protocol was performed in accordance with the institutional ethics committee.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Rodés-Cabau J. Transcatheter aortic valve implantation: current and future approaches. *Nat Rev Cardiol* 2012;**9**:15–29.
- Vahanian A, Himbert D, Brochet E. Transcatheter valve implantation for patients with aortic stenosis. *Heart* 2010;**96**:1849–56.
- Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. *Circulation* 2009;**119**:3009–16.
- Thomas M, Schymik G, Walther T, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. *Circulation* 2011;**124**:425–33.
- Gilard M, Eltchaninoff H, Lung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. *N Engl J Med* 2012;**366**:1705–15.
- Moat N, Ludman P, de Belder MA, et al. Long term outcomes after transcatheter aortic valve implantation in high risk patients with severe aortic stenosis. The UK TAVI registry. *J Am Coll Cardiol* 2011;**58**:2130–8.
- Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011;**364**:2187–98.
- Joshi GP, Bonnet F, Shah R, et al. A systematic review of randomized trials evaluating regional techniques for post-thoracotomy analgesia. *Anesth Analg* 2008;**107**:1026–40.
- Moraca RJ, Sheldon DG, Thirlby RC, et al. The role of epidural anesthesia and analgesia in surgical practice. *Ann Surg* 2003;**238**:663–73.
- Svircevic V, van Dijk D, Nierich AP, et al. Meta-analysis of thoracic epidural anesthesia versus general anesthesia for cardiac surgery. *Anesthesiology* 2011;**114**:271–82.
- Bigami E, Landoni G, Biondi-Zoccai GG, et al. Epidural analgesia improves outcome in cardiac surgery: a meta-analysis of randomized controlled trials. *J Cardiothorac Vasc Anesth* 2010;**24**:586–97.
- Mukherjee C, Walther T, Borger MA, et al. Awake transapical aortic valve implantation using thoracic epidural anesthesia. *Ann Thorac Surg* 2009;**88**:992–4.
- Rodés-Cabau J, Dumont E, De LaRochelière R, et al. Feasibility and initial results of percutaneous aortic valve implantation including selection of the transfemoral or transapical approach in patients with severe aortic stenosis. *Am J Cardiol* 2008;**102**:1240–6.
- Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines. *Reg Anesth Pain Med* 2010;**35**:64–101.
- Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. *J Am Coll Cardiol* 2011;**57**:253–69.
- Hemmerling TM, Djaiani G, Babb P, et al. The use of epidural analgesia in cardiac surgery should be encouraged. *Anesth Analg* 2006;**103**:1592–3.
- Walther T, Falk V, Metz S, et al. Pain and quality of life after minimally invasive versus conventional cardiac surgery. *Ann Thorac Surg* 1999;**67**:1643–7.
- Gogarten W. The influence of new antithrombotic drugs on regional anesthesia. *Curr Opin Anaesthesiol* 2006;**19**:545–50.
- Green L, Machin SJ. Managing anticoagulated patients during neuraxial anaesthesia. *Br J Haematol* 2010;**149**:195–208.
- Liu SS, Buvanendran A, Viscusi ER, et al. Uncomplicated removal of epidural catheters in 4365 patients with international normalized ratio greater than 1.4 during initiation of warfarin therapy. *Reg Anesth Pain Med* 2011;**36**:231–5.
- Ho MC, Beathe JC, Sharrock NE, et al. Hypotensive epidural anesthesia in patients with aortic stenosis undergoing total hip replacement. *Reg Anesth Pain Med* 2008;**33**:129–33.
- Ioscovich AM, Goldszmidt E, Fadeev AV, et al. Peripartum anesthetic management of patients with aortic valve stenosis: a retrospective study and literature review. *Int J Obstet Anesth* 2009;**18**:379–86.
- Bracco D, Noiseux N, Dubois MJ, et al. Epidural anesthesia improves outcome in cardiac surgery: a single-center study of a 1293-patient cohort. *Heart Surg Forum* 2007;**10**:E449–58.
- Amat-Santos IJ, Rodés-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. *J Am Coll Cardiol* 2012;**59**:178–88.
- Rodés-Cabau J, Gutierrez M, Bagur R, et al. Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. *J Am Coll Cardiol* 2011;**57**:1988–99.
- Richardson J, Sabanathan S, Shah R, et al. Post-thoracotomy spirometric lung function: the effect of analgesia. A review. *J Cardiovasc Surg (Torino)* 1999;**40**:445–56.
- Scarlata S, Pedone C, Conte ME, et al. Accuracy of spirometry in diagnosing pulmonary restriction in elderly people. *J Am Geriatr Soc* 2009;**57**:2011–17.
- Ballantyne JC, Carr DB, deFerranti S, et al. The comparative effects of postoperative analgesic therapies on pulmonary outcome: cumulative meta-analyses of randomized controlled trials. *Anesth Analg* 1998;**86**:598–612.
- Wijesundera DN, Beattie WS, Austin PC, et al. Epidural anaesthesia and survival after intermediate-to-high risk non-cardiac surgery: a population-based cohort study. *Lancet* 2008;**372**:562–9.
- Kempfert J, Rastan A, Holzhey D. Transapical aortic valve implantation: analysis of risk factors and learning experience in 299 patients. *Circulation* 2011;**124**(11 Suppl):S124–9.
- Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high risk patients with severe aortic stenosis: results from the PARTNER trial (cohort A). *J Am Coll Cardiol*. In press.

that the linked article (reference 6) starts on page 1483. This is an error, it should say the starting page is 1583.
doi:10.1136/heartjnl-2012-302185corr1

CORRECTIONS

Dworakowski R, Wendler O. Optimal pain management after aortic valve implantation: an opportunity to improve outcomes after transapical access in the future? *Heart* 2012;**98**:1541–1542. This editorial states